DABRAFENIB MESYLATE - Generic Drug Details

What are the generic sources for dabrafenib mesylate and what is the scope of freedom to operate?

Dabrafenib mesylate is the generic ingredient in one branded drug marketed by Novartis and is included in two NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dabrafenib mesylate has one hundred and thirty-seven patent family members in forty-two countries.

There is one drug master file entry for dabrafenib mesylate. One supplier is listed for this compound.

Summary for DABRAFENIB MESYLATE

International Patents:	137
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	2
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	15
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DABRAFENIB MESYLATE
DailyMed Link:	DABRAFENIB MESYLATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DABRAFENIB MESYLATE

Constraining patent/regulatory exclusivity:

TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY

Dosage:

CAPSULE;ORAL

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DABRAFENIB MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	PHASE2
Rising Tide Foundation	PHASE2
ECOG-ACRIN Cancer Research Group	Phase 2

See all DABRAFENIB MESYLATE clinical trials

Pharmacology for DABRAFENIB MESYLATE

Drug Class

Kinase Inhibitor

Mechanism of Action

Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C8 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Organic Anion Transporter 1 Inhibitors Organic Anion Transporter 3 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Protein Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for DABRAFENIB MESYLATE

L01EC	B-Raf serine-threonine kinase (BRAF) inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for DABRAFENIB MESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAFINLAR	Capsules	dabrafenib mesylate	50 mg and 75 mg	202806	1	2025-11-13

US Patents and Regulatory Information for DABRAFENIB MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes					Y
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes					Y
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes					Y
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes
Novartis	TAFINLAR	dabrafenib mesylate	TABLET, FOR SUSPENSION;ORAL	217514-001	Mar 16, 2023		RX	Yes	Yes					Y
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes
Novartis	TAFINLAR	dabrafenib mesylate	CAPSULE;ORAL	202806-002	May 29, 2013		RX	Yes	Yes					Y

International Patents for DABRAFENIB MESYLATE

Country	Patent Number	Title	Estimated Expiration
Israel	271513
Chile	2012000964
South Africa	201202612	COMBINATION
Spain	2745479
Dominican Republic	P2010000326
Poland	3560498
Spain	2986037

Dabrafenib Mesylate Market Dynamics and Financial Trajectory

Last updated: April 23, 2026

Dabrafenib mesylate is a BRAF inhibitor built on blockbuster-grade oncology uptake driven by melanoma and later extended into other BRAF-mutant solid tumors via label expansions and combination regimens. Public financials show sustained, high-value revenue through the core brand periods, with later growth increasingly constrained by competition, cycling patterns in BRAF/MAPK landscapes, and mix shift toward combinations and sequencing.

What is the market foundation for dabrafenib mesylate?

Dabrafenib (marketed as Tafinlar) is a targeted therapy against oncogenic BRAF V600E and BRAF V600K mutations. The mesylate salt form supports oral dosing and is the marketed drug substance behind the brand.

Core commercial demand drivers

• Mutation-driven prescribing: Use is tied to BRAF V600 mutation testing, which narrows eligible populations but improves treatment consistency for payers and clinicians.
• Combination-led adoption: The largest routine demand base has come from use in combination with trametinib for BRAF V600–mutant melanoma and from regimen evolution across the BRAF portfolio.
• Extension via label growth and real-world sequencing: Subsequent trials and broader practice patterns have expanded where and how dabrafenib-based regimens are used.

Competitive context (BRAF/MAPK)

The BRAF inhibitor landscape includes vemurafenib and encorafenib plus pathway peers and combination anchors (e.g., trametinib class). Over time, pricing and access dynamics shift toward the most durable combinations and regimens with the strongest overall benefit-risk profiles.

How has financial performance evolved for the dabrafenib franchise?

Public company reporting ties dabrafenib to the Novartis product stack during key periods and to the GSK stack during other periods through corporate ownership changes and shared oncology commercial structures. The market trajectory is best read through brand revenue performance and portfolio reporting.

Brand and company reporting cadence

• Dabrafenib’s commercial history is reflected in annual reports and investor materials through the revenue line items tied to Tafinlar and related combination products (where reported).
• Combination partners (notably trametinib) often move together in reimbursement and sequencing decisions, which affects financial mix.

Revenue trajectory (high-level)

• Peak/scale years: Dabrafenib entered the market with fast uptake characteristic of first-wave precision oncology. Early sales were supported by high-confidence mutation testing infrastructure and clear clinical positioning.
• Post-expansion growth: Sales continued to grow as melanoma indications matured and as combination strategies became standard-of-care in eligible settings.
• Later plateau risk factors: Growth later faced pressure from competitive entrants in the BRAF class, payer preference shifts tied to value frameworks, and patient attrition as the treatment line shifted to newer regimens.

What are the key market dynamics shaping uptake and pricing power?

1) Indication mix and BRAF testing penetration

• BRAF V600 mutation testing capacity is now routine in major oncology centers, supporting stable eligible populations.
• Uptake is sensitive to guideline adoption and local test panel availability. Regions with broader NGS or reflex testing tend to convert eligible patients more reliably.

2) Combination regimen economics

Dabrafenib is used most commercially in combination settings where:

• Total regimen cost and clinical benefit drive payer coverage decisions.
• Dose intensity management and discontinuation rates influence effective realized net revenue per patient.

3) Competitive switching and sequencing

BRAF/MAPK oncology is prone to switching because:

• Multiple agents show activity in the same molecular subgroup.
• Second-line and later-line availability changes the order of use.
• Evolving clinical evidence shifts preference toward specific combinations.

4) Net price and reimbursement frameworks

Across major markets, net revenue reflects:

• Contract rebates and outcomes-based frameworks
• Tendering dynamics in certain European markets
• Formulary tiering in the US based on PBM influence and manufacturer contracting

These mechanisms tend to compress peak pricing power after initial launch periods.

What financial trajectory patterns matter most to investors?

Durable demand pattern

Dabrafenib benefits from:

• A biomarker-defined market
• Long-term use in melanoma regimens that remain embedded in treatment algorithms
• Combination reliance, which stabilizes demand versus monotherapy-only products

Erosion/slowdown pattern

Financial performance typically faces:

• Incremental share loss to competing BRAF combinations
• Sequencing shifts as additional evidence and alternatives mature
• Margin pressure from increased access pressure and value re-assessments

Mix shift from single-agent to combo and line-of-therapy

Financial results can improve or worsen depending on:

• The share of patients treated in the most reimbursed settings
• The proportion of combination use versus monotherapy, where net pricing differs
• The timing of patent-expiration and competition cycles in each geography

How does the ownership and commercialization landscape affect results?

Dabrafenib is marketed as Tafinlar. Commercial reporting and negotiation leverage depend on corporate structure, manufacturing footprint, and oncology commercialization maturity.

Corporate attribution in public sources

• Dabrafenib’s commercial story is tracked through issuer financials and investor disclosures connected to the branded oncology product lines. (See sources in the reference list.)
• Patent and exclusivity events shape competitive headwinds and the ability to sustain pricing.

What patent and exclusivity milestones are most relevant to cash-flow visibility?

Patent life and regulatory exclusivity drive:

• The duration of monopoly revenue windows
• The timing of biosimilar-like substitution risk (for biologics) does not apply, but small-molecule competitive entry does
• The pace of generic erosion if exclusivity barriers are overcome

The mesylate salt form is typically supported by drug substance and composition claims, plus formulation and method-of-use coverage, with additional layers from combination claims depending on jurisdiction.

What are the practical market metrics to track going forward?

Investors typically monitor:

• US and EU net sales for Tafinlar and combo regimens
• Share of use driven by guideline updates and NGS penetration
• Reimbursement status changes by payer and PBM contracting outcomes
• Safety-management driven discontinuation rates (which influence effective treatment duration)

Key Takeaways

• Dabrafenib mesylate’s market foundation is biomarker-defined oncology with high conversion enabled by BRAF V600 testing and sustained clinical integration in combination regimens.
• Financial trajectory shows launch-driven scale followed by expansion supported by label and regimen adoption, then a later plateau risk shaped by BRAF class competition, payer value pressure, and sequencing.
• Combination-led uptake stabilizes demand but increases dependence on overall regimen reimbursement economics and patient persistence.
• Patent and exclusivity timelines determine the length of cash-flow visibility and the pace of erosion as competitive BRAF options intensify.

FAQs

1) Where does dabrafenib generate the majority of commercial demand?

The commercial demand is concentrated in melanoma treatment settings where BRAF V600 mutation selection and combination regimens with trametinib are standard practice.

2) What drives payer decisions for dabrafenib-based therapy?

Payers focus on evidence-based benefit in biomarker-selected populations, regimen-level cost-effectiveness, and realized net pricing driven by contracting terms and rebates.

3) Why does sequencing matter for dabrafenib revenue?

Later-line and post-progression treatment patterns affect how many patients receive dabrafenib versus competitor BRAF combinations, altering share and realized revenue per patient.

4) How does competition in the BRAF class affect financial outcomes?

Competitive switching changes share, and new combination options can reduce the proportion of patients initiating on dabrafenib-based therapy, especially after label maturity and value assessments.

5) What are the main levers for sustaining sales growth beyond launch?

Sustaining growth depends on continued label/regimen fit, maintaining payer coverage, optimizing patient persistence and dosing tolerability, and protecting share through combination strategy and clinical sequencing.

References

[1] Novartis. (n.d.). Tafinlar (dabrafenib) prescribing information and related safety/clinical data. https://www.novartis.com/
[2] U.S. Food and Drug Administration. (n.d.). Tafinlar (dabrafenib) label and regulatory information. https://www.accessdata.fda.gov/
[3] European Medicines Agency. (n.d.). Tafinlar (dabrafenib) EPAR and regulatory history. https://www.ema.europa.eu/
[4] Novartis. (n.d.). Annual reports and financial results for oncology product lines referencing Tafinlar. https://www.novartis.com/investors
[5] GSK. (n.d.). Corporate and investor materials referencing Tafinlar commercialization history in reporting periods. https://www.gsk.com/